THOC3 interacts with YBX1 to promote lung squamous cell carcinoma progression through PFKFB4 mRNA modification.


Journal

Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092

Informations de publication

Date de publication:
27 07 2023
Historique:
received: 08 01 2023
accepted: 17 07 2023
revised: 13 07 2023
medline: 31 7 2023
pubmed: 28 7 2023
entrez: 27 7 2023
Statut: epublish

Résumé

The THO complex (THOC) is ubiquitously involved in RNA modification and various THOC proteins have been reported to regulate tumor development. However, the role of THOC3 in lung cancer remains unknown. In this study, we identified that THOC3 was highly expressed in lung squamous cell carcinoma (LUSC) and negatively associated with prognosis. THOC3 knockdown inhibited LUSC cell growth, migration, and glycolysis. THOC3 expression was regulated by TRiC proteins, such as CCT8 and CCT6A, which supported protein folding. Furthermore, THOC3 could form a complex with YBX1 to promote PFKFB4 transcription. THOC3 was responsible for exporting PFKFB4 mRNA to the cytoplasm, while YBX1 ensured the stability of PFKFB4 mRNA by recognizing m5C sites in its 3'UTR. Downregulation of PFKFB4 suppressed the biological activities of LUSC. Collectively, these findings suggest that THOC3, folded by CCT proteins can collaborate with YBX1 to maintain PFKFB4 expression and facilitate LUSC development. Therefore, THOC3 could be considered as a novel promising therapeutic target for LUSC.

Identifiants

pubmed: 37500615
doi: 10.1038/s41419-023-06008-3
pii: 10.1038/s41419-023-06008-3
pmc: PMC10374565
doi:

Substances chimiques

CCT6A protein, human 0
Chaperonin Containing TCP-1 EC 3.6.1.-
PFKFB4 protein, human 0
Phosphofructokinase-2 EC 2.7.1.105
Phosphoric Monoester Hydrolases EC 3.1.3.2
RNA, Messenger 0
Y-Box-Binding Protein 1 0
YBX1 protein, human 0
Tex1 protein, human 0
RNA-Binding Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

475

Informations de copyright

© 2023. The Author(s).

Références

Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
Oncogene. 2021 Sep;40(39):5814-5828
pubmed: 34345012
PLoS Genet. 2010 Dec 23;6(12):e1001250
pubmed: 21203492
J Obstet Gynaecol. 2022 Aug;42(6):2399-2405
pubmed: 35659173
Ann Clin Lab Sci. 2008 Spring;38(2):105-12
pubmed: 18469354
Blood. 2021 Jul 8;138(1):71-85
pubmed: 33763698
J Thorac Oncol. 2020 Nov;15(11):1748-1757
pubmed: 32717408
Structure. 2012 May 9;20(5):814-25
pubmed: 22503819
Trends Cell Biol. 2022 Sep;32(9):786-799
pubmed: 35300892
Nat Cell Biol. 2019 Aug;21(8):978-990
pubmed: 31358969
Cell Death Dis. 2020 Jun 19;11(6):476
pubmed: 32561752
Nat Struct Mol Biol. 2008 Dec;15(12):1255-62
pubmed: 19011634
Oncogenesis. 2021 Dec 3;10(12):84
pubmed: 34862361
Nucleic Acids Res. 2021 Jul 2;49(W1):W72-W79
pubmed: 34086933
Nucleic Acids Res. 2022 Jan 7;50(D1):D1522-D1527
pubmed: 34871441
Nucleic Acids Res. 2019 Jan 8;47(D1):D1211-D1217
pubmed: 30252093
Nature. 2018 Apr;556(7700):249-254
pubmed: 29615789
Adv Sci (Weinh). 2021 Dec;8(24):e2102658
pubmed: 34708581
Anesthesiology. 2008 Mar;108(3):467-72
pubmed: 18292684
Cancers (Basel). 2021 Feb 22;13(4):
pubmed: 33671514
BMC Pulm Med. 2021 Feb 16;21(1):60
pubmed: 33593309
Cell Death Dis. 2021 Jan 4;12(1):29
pubmed: 33414399
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Int J Gen Med. 2022 Mar 08;15:2695-2713
pubmed: 35300138
Cancer Treat Rev. 2015 Jun;41(6):527-39
pubmed: 25959741
Nature. 2002 May 16;417(6886):304-8
pubmed: 11979277
EMBO J. 2019 May 2;38(9):
pubmed: 30858280
Carcinogenesis. 2020 Jun 17;41(4):405-416
pubmed: 32347301
Oncogene. 2020 Jan;39(1):136-150
pubmed: 31462707
Nat Commun. 2019 Jun 11;10(1):2550
pubmed: 31186410
J Natl Cancer Inst. 2014 Oct 08;106(11):
pubmed: 25296641
Oncogene. 2012 Jul 5;31(27):3235-43
pubmed: 22056879
N Engl J Med. 2019 Aug 22;381(8):727-738
pubmed: 31433920
PLoS Biol. 2014 Apr 22;12(4):e1001844
pubmed: 24756126
Cell Res. 2017 May;27(5):606-625
pubmed: 28418038
Gene. 2020 Mar 30;732:144350
pubmed: 31935505
Nat Genet. 2017 Dec;49(12):1779-1784
pubmed: 29083409
Cancer Med. 2021 Oct;10(20):7418-7439
pubmed: 34482648
Oncogene. 2022 Aug;41(32):3899-3911
pubmed: 35794249
J Exp Clin Cancer Res. 2022 Apr 11;41(1):136
pubmed: 35410432
BMC Biol. 2020 Apr 15;18(1):40
pubmed: 32293435

Auteurs

Tao Yu (T)

Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, China.

Qi Zhang (Q)

Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, China.
Department of Oncology, the Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, China.

Shao-Kun Yu (SK)

Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, China.

Feng-Qi Nie (FQ)

Department of Oncology, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Mei-Ling Zhang (ML)

Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, China.

Qian Wang (Q)

Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, China.

Kai-Hua Lu (KH)

Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, China. lukaihua@njmu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH